ADIAL PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $2.6M | $3.2M | $1.3M | $2.0M | $8.4M |
| Operating expenses | $7.8M | $8.3M | $6.9M | $10.9M | $19.3M |
| Operating income | -$7.8M | -$8.3M | -$6.9M | -$10.9M | -$19.3M |
| Pretax income | -$8.0M | -$13.2M | -$7.0M | -$10.8M | -$19.5M |
| Income tax expense | — | — | — | -$502 | -$94,077 |
| Net income | -$8.0M | -$13.2M | -$5.1M | -$12.7M | -$19.4M |
| Balance Sheet | |||||
| Cash and equivalents | $5.9M | $3.8M | $2.8M | $4.0M | $6.1M |
| Current assets | $6.2M | $4.1M | $3.2M | $4.8M | $6.5M |
| Total assets | $6.7M | $5.0M | $4.7M | $5.7M | $7.5M |
| Current liabilities | $1.4M | $975,858 | $653,076 | $1.8M | $2.7M |
| Total liabilities | $1.4M | $975,858 | $653,076 | $2.5M | $4.0M |
| Stockholders' equity | $5.3M | $4.1M | $4.1M | $3.3M | $3.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$6.5M | -$6.9M | -$6.8M | -$11.2M | -$11.9M |
| Stock-based compensation | $676,200 | $796,831 | $1.7M | $3.4M | $4.2M |
| Capital expenditure | — | — | — | — | $64,605 |
| Free cash flow | — | — | — | — | -$12.0M |
| Share repurchases | — | — | $1,661 | — | — |
| Impairments | — | — | — | — | $1.5M |
Shares outstanding 2.1M
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.